


GaCl₃-Catalyzed Allenyne Cycloisomerizations to Allenenes

Sang Ick Lee, So Hee Sim, Soo Min Kim, Kwang Kim, and Young Keun Chung*

Intelligent Textile System Research Center and Department of Chemistry, College of Natural Sciences, Seoul National University, Seoul 151-747, Korea

ykchung@snu.ac.kr

Received June 27, 2006



Cycloisomerizations of allenynes to allenenes have been studied in the presence of catalytic amounts of [Au(PPh₃)]SbF₆ in dichloromethane or GaCl₃ in toluene. Both catalytic systems are quite effective for terminal 1,6-allenynes. However, they showed different reactivities toward allenynes with di-substituents at the allenic terminal carbon. For the GaCl₃-catalyzed reactions, allenenes were obtained in reasonable to high yields. However, for a Au(I)-catalyzed reaction, a triene was obtained in a poor yield. Thus, GaCl₃ serves as an effective catalyst for the cycloisomerization of allenynes bearing a terminal alkyne to give cyclic allenenes in reasonable to high yields.

The transition-metal-catalyzed cyclization of enyne systems has recently experienced tremendous developments.¹ Allenynes are quite attractive substrates due to their use in diverse synthetic applications as well as in new reactions of unsaturated systems.² Recently, they have been widely used in intramolecular Pauson–Khand reactions.³ However, allenynes still have been much less involved in the transition-metal-catalyzed (or -mediated) cyclizations than their enyne analogues. Particularly, transition-metal-catalyzed intramolecular cycloisomerizations of enynes have recently been widely studied.⁴ However, the use of

allenynes in the metal-catalyzed cycloisomerization is quite rare. Recently, PtCl₂-catalyzed cycloisomerizations of allenynes were reported by Murakami's and Malacria's groups.⁵ We initially studied the use of gold-catalyzed cycloisomerization of allenynes. However, the expected reaction did not proceed in many cases. This limitation prompted us to investigate an alternative, more reactive catalytic system. Herein, we describe a cycloisomerization of allenynes upon treatment with a catalytic amount of GaCl₃. Recently, the Chatani group reported⁶ that GaCl₃ is a highly active catalyst for the skeletal rearrangement of 1,6-enynes and 1,7-enynes.

We initially screened various metal catalysts such as the Grubbs catalyst,⁷ Au(L)Cl/AgX,⁴ FeCl₃,⁸ PtCl₂,⁵ InCl₃,⁹ GaCl₃,⁶ and [Mn(CO)₅]BF₄¹⁰ for the cycloisomerization of allenynes (Table 1).

Unfortunately, when PtCl₂, [Mn(CO)₅]BF₄, or FeCl₃ was used as a catalyst, the reactant was recovered. The use of Grubbs catalyst led to polymerization of the reactant. When InCl₃ was used as a catalyst, 45% of the cycloisomerized product was isolated with a recovery of 40% of the reactant. However, when [Au(PPh₃)]SbF₆ and GaCl₃ were used as a catalyst, the metath-

(3) (a) Mukai, C.; Hirose, T.; Teramoto, S.; Kitagaki, S. *Tetrahedron* **2005**, *61*, 10983. (b) Brummond, K. M.; Curran, D. P.; Mitasev, B.; Fischer, S. J. *Org. Chem.* **2005**, *70*, 1745. (c) Cao, H.; Van Ornum, S. G.; Deschamps, J.; Flippen-Anderson, J.; Laib, F.; Cook, J. M. *J. Am. Chem. Soc.* **2005**, *127*, 933. (d) Alcaide, B.; Almendros, P. *Eur. J. Org. Chem.* **2004**, 3377. (e) Brummond, K. M.; Gao, D. *Org. Lett.* **2003**, *5*, 3491. (f) Brummond, K. M.; Kerekes, A. D.; Wan, H. *J. Org. Chem.* **2002**, *67*, 5156. (g) Brummond, K. M.; Chen, H. F.; Fisher, K. D.; Kerekes, A. D.; Rickards, B.; Sill, P. C.; Geib, S. J. *Org. Lett.* **2002**, *4*, 1931. (h) Mukai, C.; Nomura, I.; Yamanishi, K.; Hanaoka, M. *Org. Lett.* **2002**, *4*, 1755. (i) Brummond, K. M.; Lu, J. L.; Petersen, J. J. *Am. Chem. Soc.* **2000**, *122*, 4915. (j) Brummond, K. M.; Lu, J. L. *J. Am. Chem. Soc.* **1999**, *121*, 5087. (k) Brummond, K. M.; Wan, H. *Tetrahedron Lett.* **1998**, *39*, 931. (l) Kent, J. L.; Wan, H. H.; Brummond, K. M. *Tetrahedron Lett.* **1995**, *36*, 2407.

(4) For reviews, see: (a) Diver, S. T.; Giessert, A. J. *Chem. Rev.* **2004**, *104*, 1317. (b) Lloyd-Jones, G. C. *Org. Biomol. Chem.* **2003**, *1*, 215. (c) Aubert, C.; Buisine, O.; Malacria, M. *Chem. Rev.* **2002**, *102*, 813. (d) Trost, B. M.; Toste, F. D.; Pinkerton, A. B. *Chem. Rev.* **2001**, *101*, 2067. (e) Trost, B. M.; Krische, M. J. *Synlett* **1998**, 1. For Au- and Pt-catalyzed enyne cycloisomerizations, see: (f) Echavarren, A. M.; Nevado, C. *Chem. Soc. Rev.* **2004**, *33*, 431. (g) Nieto-Oberhuber, C.; López, S.; Echavarren, A. M. *J. Am. Chem. Soc.* **2005**, *127*, 6179. (h) Muñoz, M. P.; Adrio, J.; Carretero, J. C.; Echavarren, A. M. *Organometallics* **2005**, *24*, 1293. (i) Nieto-Oberhuber, C.; Muñoz, M. P.; Buñuel, E.; Nevado, C.; Cárdenas, D. J.; Echavarren, A. M. *Angew. Chem., Int. Ed.* **2004**, *43*, 2402. (j) Méndez, M.; Muñoz, M. P.; Nevado, C.; Cárdenas, D. J.; Echavarren, A. M. *J. Am. Chem. Soc.* **2001**, *123*, 10511. (k) Oi, S.; Tsukamoto, I.; Miyano, S.; Inoue, Y. *Organometallics* **2001**, *20*, 3704.

(5) (a) Matsuda, T.; Kadowaki, S.; Goya, T.; Murakami, M. *Synlett* **2006**, 575. (b) Cadran, N.; Cariou, K.; Hervé, G.; Aubert, C.; Fensterbank, L.; Malacria, M.; Marco-Contelles, J. *J. Am. Chem. Soc.* **2004**, *126*, 3408.

(6) (a) Mamane, V.; Hannen, P.; Fürstner, A. *Chem. Eur. J.* **2004**, *10*, 4556. (b) Chatani, N.; Oshita, M.; Tobisu, M.; Ishii, Y.; Murai, S. *J. Am. Chem. Soc.* **2003**, *125*, 7812. (c) Chatani, N.; Inoue, H.; Kotsuma, T.; Murai, S. *J. Am. Chem. Soc.* **2002**, *124*, 10294. (d) Fürstner, A.; Mamane, V. *J. Org. Chem.* **2002**, *67*, 6264. (e) Inoue, H.; Chatani, N.; Murai, S. *J. Org. Chem.* **2002**, *67*, 1414.

(7) (a) Peppers, B. P.; Diver, S. T. *J. Am. Chem. Soc.* **2004**, *126*, 9524. (b) Schmidt, B. *Angew. Chem., Int. Ed.* **2003**, *42*, 4996. (c) Kitamura, T.; Sato, Y.; Mori, M. *Adv. Synth. Catal.* **2002**, *344*, 678. (d) Mori, M.; Sakakibara, N.; Kinoshita, A. *J. Org. Chem.* **1998**, *63*, 6082. (e) Kinoshita, A.; Mori, M. *Synlett* **1994**, 1020.


(8) Nieto-Oberhuber, C.; Muñoz, M. P.; López, S.; Jiménez-Núñez, E.; Nevado, C.; Herrero-Gómez, E.; Raducan, M.; Echavarren, A. M. *Chem. Eur. J.* **2006**, *12*, 1677.

(9) Miyano, Y.; Chatani, N. *Org. Lett.* **2006**, *8*, 2155.

(10) Recently, we found that [Mn(CO)₅]BF₄ was active in the cycloisomerization of some enyne substrates. Lee, S. I.; Baek, J. Y.; Chung, Y. K. Manuscript in preparation.

(1) For reviews, see: (a) Nakamura, I.; Yamamoto, Y. *Chem. Rev.* **2004**, *104*, 2127. (b) Frühauf, H.-W. *Chem. Rev.* **1997**, *97*, 523. (c) Ojima, I.; Zamariondaki, M.; Li, Z.; Donovan, R. J. *Chem. Rev.* **1996**, *96*, 635. (d) Lautens, M.; Klute, W.; Tam, W. *Chem. Rev.* **1996**, *96*, 49.

(2) (a) Brummond, K. M.; You, L. F. *Tetrahedron* **2005**, *61*, 6180. (b) Gupta, A. K.; Rhim, C. Y.; Oh, C. H. *Tetrahedron Lett.* **2005**, *46*, 2247. (c) Oh, C. H.; Park, D. I.; Jung, S. H.; Reddy, V. R.; Gupta, A. K.; Kim, Y. M. *Synlett* **2005**, 2092. (d) Kumareswaran, R.; Shin, S.; Gallou, I.; RajanBabu, T. V. *J. Org. Chem.* **2004**, *69*, 7157. (e) Shibata, T.; Kadowaki, S.; Takagi, K. *Organometallics* **2004**, *23*, 4116. (f) Mukai, C.; Inagaki, F.; Yoshida, T.; Kitagaki, S. *Tetrahedron Lett.* **2004**, *45*, 4117. (g) Oh, C. H.; Jung, S. H.; Park, D. I.; Choi, J. H. *Tetrahedron Lett.* **2004**, *45*, 2499. (h) Oh, C. H.; Jung, S. H.; Rhim, C. Y. *Tetrahedron Lett.* **2001**, *42*, 8669. (i) Urabe, H.; Takeda, T.; Hideura, D.; Sato, F. *J. Am. Chem. Soc.* **1997**, *119*, 11295.

TABLE 1. Allenyne Metathesis by Various Catalysts^a


entry	catalyst	solvent	T (°C)	t (h)	yield (%) ^b
1	5 mol % RuCl ₂ (PCy ₃) ₂ - (benzylidene)	CH ₂ Cl ₂	15–20	6	N/A
2	5 mol % [Mn(CO) ₅]BF ₄	DCE	60	24	NR
3	5 mol % FeCl ₃	toluene	80	24	NR
4	5 mol % PtCl ₂	toluene	80	24	NR
5	10 mol % InCl ₃	toluene	80	24	45(40)
6	5 mol % [Au(PPh ₃) ₃]SbF ₆	CH ₂ Cl ₂	15–20	0.5	75
7	10 mol % GaCl ₃	toluene	15–20	2	81

^a 0.2 g (0.691 mmol) of **1a** in 5 mL of solvent was used. ^b Isolated yield. ^c DCE = 1,2-dichloroethane. ^d Yield in parentheses is reactant recovered.


esis product was isolated in 75% and 81% yield, respectively. The obtained cycloisomerized product (**1A**) was the same type as those obtained by the molybdenum alkylidene complex-catalyzed ring-closing metathesis (RCM) of allenynes¹¹ but quite different from those obtained by PtCl₂-catalyzed cycloisomerization of allenynes.⁵ Encouraged by this result, several allenynes were examined for GaCl₃- and Au(I)-catalyzed metathesis reactions (Table 2).

Terminal allenynes **1a–1c** having sulfonamide or sulfone in a tether were found to serve as good substrates for both GaCl₃- and Au(I)-catalyzed reactions (entries 1–5). This is in sharp contrast to previously reported results on the Mo-catalyzed RCM of allenynes,¹¹ where no reaction occurred with allenynes bearing the allenic terminus unsubstituted. Allenynes **1d–1g** having a substituent on the 3 position (entries 6–10) or having a substituent on the 5 position (entries 11 and 12) were also good substrates. However, allenynes with di-substituents at the allenic terminal carbon showed a different behavior depending upon the catalyst used. When GaCl₃ was used as catalyst, an allenyne (**1h**) (entry 13) afforded the product **2h** in 60% yield and allenynes **1i** and **1j** bearing a cyclic group on the allenic terminal carbon (entries 14 and 15) were also good substrates and led to the isolation of the products **2i** and **2j** in 53% and 83% yields, respectively. Thus, substantial structural variations can be accommodated. Interestingly, when **1j** was reacted with [Au(PPh₃)₃]SbF₆, a cycloisomerized product (**3j**) was isolated in low yield (38%). This transformation is similar to the PtCl₂-catalyzed cycloisomerization of allenynes reported by Murakami's group.^{5a} Thus, GaCl₃ is a better catalyst for the cycloisomerization of allenynes with di-substituents at the allenic terminal carbon. Unfortunately, no reaction was observed for allenynes having a substituent (**1k** and **1l**) on the alkyne terminal position (entries 17–19) and a 1,7-allenynes (**1m**) (entries 20 and 21) under the conditions described here.


When allenene (**1n**) was reacted in the presence of GaCl₃ catalyst (Scheme 1), an RCM product (**3n**) was obtained in 22% yield with recovery of reactant in 76% yield. However, no reaction was observed in the presence of Au(I) catalyst. Treatment of 1,6-diene (**1o**) under the same reaction conditions gave no reaction product. Thus, the GaCl₃- and Au(I)-catalyzed cycloisomerization were unique to allenyne substrates.

When allenyne **1a-d** with the alkyne terminus deuterated was used, the deuterium was labeled at the 1-position of the produced


SCHEME 1



allene (eq 1). Murakami et al.¹¹ also observed the formation of the same deuterated reaction product.



Next, when a crossover reaction using a mixture of **1h** and **1j** was carried out in the presence of GaCl₃, no crossover products were obtained (eq 2). This observation was quite different from the results observed in the molybdenum-catalyzed reaction, where the crossover products were isolated.⁶



A general mechanistic view has so far remained elusive. However, our experimental observations suggest that the mechanism will be different from that proposed by Murakami¹¹ but will follow the general process depicted by Chatani⁶ (Scheme 2).¹²

In conclusion, we have shown that the unprecedented GaCl₃- and Au(I)-catalyzed cycloisomerization of allenyne systems is a highly versatile tool for obtaining products that cannot be easily attained with other metals. Both catalytic systems are quite effective for terminal 1,6-allenynes. However, they showed different reactivities toward allenynes with di-substituents at the allenic terminal carbon.

Experimental Section

General Procedure for GaCl₃-Catalyzed Metathesis of Allenyne. To a flame-dried 10 mL Schlenk containing 5 mL of toluene were added GaCl₃ (10 mol %, 14 mg) and allenyne (0.7 mmol) sequentially. After the reactant disappeared, 1 mL of diisopropylamine was added. After the reaction mixture was quenched, the solvent was removed under reduced pressure. Flash column chromatography gave the product.

General Procedure for AuCl(PPh₃)/AgSbF₆-Catalyzed Metathesis of Allenyne. To a flame-dried 10 mL Schlenk containing

(12) One of the referees suggested an alternative, path "b", as a possible reaction path.


(11) Murakami, M.; Kadowaki, S.; Matsuda, T. *Org. Lett.* **2005**, *7*, 3953.

TABLE 2. GaCl₃- and [Au(PPh₃)]SbF₆-Catalyzed Metathesis of Allenyne^a

Entry	Reactant	Product	Catalyst	T(°C)	t	Yield(%) ^b
1		X= NTs (2a)	GaCl ₃	20	2 h	81
2	(1a)		[Au(PPh ₃)]SbF ₆	20	30 min	75
3	X= NMts ^c (1b)	X= NMts (2b)	GaCl ₃	60	30 min	73
4	X=C(SO ₂ Ph) ₂ (1c)	X=C(SO ₂ Ph) ₂ (2c)	GaCl ₃	20	2 h	73
5	(1c)	(2c)	[Au(PPh ₃)]SbF ₆	20	30 min	56
6		R ₁ =Me (2d)	GaCl ₃	60	1 h	87
7	(1d)		[Au(PPh ₃)]SbF ₆	20	30 min	78
8	R ₁ =Et (1e)	R ₁ =Et (2e)	GaCl ₃	60	1 h	65
9	R ₁ =Ph (1f)	R ₁ =Ph (2f)	GaCl ₃	60	1 h	58
10	(1f)	(2f)	[Au(PPh ₃)]SbF ₆	20	30 min	62
11			GaCl ₃	20	2 h	77
12	(1g)	(2g)	[Au(PPh ₃)]SbF ₆	20	30 min	75
13 ^c		R ₁ =Me (2h)	GaCl ₃	20	1.5 h	60
14	R ₁ =-(CH ₂) ₃ - (1i)	R ₁ =-(CH ₂) ₃ - (2i)	GaCl ₃	20	1.5 h	53
15	R ₁ =-(CH ₂) ₅ - (1j)	R ₁ =-(CH ₂) ₅ - (2j)	GaCl ₃	20	1.5 h	83
16	(1j)		[Au(PPh ₃)]SbF ₆	20	1 h	38
17		N/A	GaCl ₃	60	24 h	N.R ^d
18	(1k)	N/A	[Au(PPh ₃)]SbF ₆	20	24 h	N.R
19	R ₁ =Ph (1l)	N/A	GaCl ₃	60	24 h	N.R
20		N/A	GaCl ₃	60	24 h	N.R
21	(1m)	N/A	[Au(PPh ₃)]SbF ₆	20	24 h	N.R

^a Condition A: 0.2 g (0.691 mmol) of allenyne and 10 mol % GaCl₃ in 5 mL of toluene were used. Condition B: 0.2 g (0.691 mmol) of allenyne, 5 mol % AuCl(PPh₃), and 7 mol % AgSbF₆ in 5 mL of CH₂Cl₂ were used. ^b Isolated yield. ^c 20 mol % GaCl₃ was used. ^d No reaction.

SCHEME 2



5 mL of CH₂Cl₂ were added AuCl(PPh₃) (5 mol %, 9 mg), AgSbF₆ (7 mol %, 10 mg), and allenyne (0.7 mmol) sequentially. After the reactant disappeared, the solvent was removed under reduced pressure. A flash column chromatography gave the product.

3-(Propa-1,2-dienyl)-1-tosyl-2,5-dihydro-1H-pyrrole (2a). ¹H NMR (CDCl₃, 300 MHz) δ 2.35 (s, 3 H), 4.02 (m, 2 H), 4.09 (m, 2 H), 4.93 (m, 2 H), 5.42 (s, 1 H), 5.80 (t, *J* = 6.6 Hz, 1 H), 7.25 (d, *J* = 8.0 Hz, 2 H), 7.65 (d, *J* = 8.2 Hz, 2 H) ppm; ¹³C NMR (CDCl₃, 75 MHz) δ 21.7, 54.8, 55.7, 78.5, 87.8, 120.7, 127.6, 130.0, 133.0, 134.2, 143.7, 211.0 ppm. Exact mass for (C₁₄H₁₅N₁S₁O₂, EI): (calcd) 261.0823, (found) 261.0825.

N-(Buta-2,3-dienyl)-2,4,6-trimethyl-N-(prop-2-ynyl)benzenesulfonamide (1b). ¹H NMR (CDCl₃, 300 MHz) δ 2.19 (t, *J* = 2.2 Hz, 1 H), 2.29 (s, 3 H), 2.57 (s, 6 H), 3.85 (m, 2 H), 4.01 (d, *J* = 2.2 Hz, 2 H), 4.77 (m, 2 H), 5.02 (m, 1 H), 6.92 (s, 2 H) ppm; ¹³C NMR (CDCl₃, 75 MHz) δ 21.0, 22.8, 34.6, 44.7, 73.0, 76.3, 85.3, 132.0, 132.3, 140.5, 142.8, 209.9 ppm. Exact mass for (C₁₆H₁₉N₁S₁O₂, EI): (calcd) 289.1137, (found) 289.1133.

1-(Mesitylsulfonyl)-3-(propa-1,2-dienyl)-2,5-dihydro-1H-pyrrole (2b). ¹H NMR (CDCl₃, 300 MHz) δ 2.29 (s, 3 H), 2.63 (s, 6 H), 4.09 (m, 2 H), 4.13 (m, 2 H), 4.98 (m, 1 H), 5.59 (s, 1 H), 5.94 (m, 1 H), 6.96 (s, 3 H) ppm; ¹³C NMR (CDCl₃, 75 MHz) δ 21.0,

22.9, 53.3, 54.3, 78.3, 87.8, 120.6, 131.9, 132.6, 132.7, 140.2, 142.5, 210.8. Exact mass for (C₁₆H₁₉N₁S₁O₂, EI): (calcd) 289.1137, (found) 289.1140.

1c. ¹H NMR (CDCl₃, 300 MHz) δ 1.94 (t, *J* = 2.1 Hz, 1 H), 2.93 (m, 2 H), 3.03 (d, *J* = 2.1 Hz, 2 H), 4.63 (m, 2 H), 5.26 (m, 1 H), 7.40 (m, 4 H), 7.53 (d, *J* = 7.4 Hz, 2 H), 7.95 (d, *J* = 8.0 Hz, 4 H) ppm; ¹³C NMR (CDCl₃, 75 MHz) δ 20.9, 29.2, 74.5, 75.7, 76.0, 83.0, 88.4, 128.7, 131.5, 135.0, 136.4, 210.5 ppm. Exact mass for (C₂₀H₁₈N₁S₁O₂, EI): (calcd) 386.0647, (found) 386.0651.

2c. ¹H NMR (CDCl₃, 300 MHz) δ 3.36–3.37 (m, 4 H), 4.97 (m, 2 H), 5.11 (s, 1 H), 5.66 (m, 1 H), 7.54 (m, 4 H), 7.67 (m, 1 H), 7.97 (m, 4 H) ppm; ¹³C NMR (CDCl₃, 75 MHz) δ 39.1, 39.5, 78.4, 89.3, 91.3, 122.8, 129.0, 131.0, 134.9, 135.1, 137.0, 211.3 ppm. Exact mass for (C₂₀H₁₈N₁S₁O₂, EI): (calcd) 386.0647, (found) 386.0651.

***N*-(But-3-yn-2-yl)-*N*-(buta-2,3-dienyl)-4-methylbenzenesulfonamide (1d).** ¹H NMR (CDCl₃, 300 MHz) δ 1.49 (d, *J* = 7.1 Hz, 3 H), 2.15 (d, *J* = 2.2 Hz, 1 H), 2.43 (s, 3 H), 3.78 (m, 1 H), 3.97 (m, 1 H), 4.78 (m, 2 H), 4.90 (dd, *J* = 7.1, 2.2 Hz, 1 H), 5.23 (m, 1 H), 7.30 (d, *J* = 8.0 Hz, 2 H), 7.74 (d, *J* = 7.9 Hz, 2 H) ppm; ¹³C NMR (CDCl₃, 75 MHz) δ 21.8, 22.8, 44.0, 46.0, 73.4, 76.6, 81.5, 89.3, 127.7, 129.7, 136.6, 143.6, 208.9 ppm. Exact mass for (C₁₅H₁₆N₁S₁O₂, EI): (calcd) 275.0980, (found) 275.0982.

2-Methyl-3-(propa-1,2-dienyl)-1-tosyl-2,5-dihydro-1H-pyrrole (2d). ¹H NMR (CDCl₃, 300 MHz) δ 1.49 (d, *J* = 6.6 Hz, 3 H), 2.43 (s, 3 H), 4.07–4.24 (m, 2 H), 4.54 (m, 1 H), 5.01 (m, 2 H), 5.45 (s, 1 H), 5.82 (t, *J* = 6.6 Hz, 1 H), 7.31 (d, *J* = 8.0 Hz, 2 H), 7.72 (d, *J* = 7.9 Hz, 2 H) ppm; ¹³C NMR (CDCl₃, 75 MHz) δ 21.6, 22.3, 54.5, 63.0, 78.5, 87.4, 120.3, 127.3, 129.8, 135.1, 143.5, 210.7 ppm. Exact mass for (C₁₅H₁₆N₁S₁O₂, EI): (calcd) 275.0980, (found) 275.0982.

***N*-(Buta-2,3-dienyl)-4-methyl-*N*-(pent-1-yn-3-yl)benzenesulfonamide (1e).** ¹H NMR (CDCl₃, 300 MHz) δ 1.02 (t, *J* = 7.7 Hz, 3 H), 1.77 (qd, *J* = 7.7, 3.3 Hz, 2 H), 2.13 (d, *J* = 2.2 Hz, 1 H), 2.41 (s, 3 H), 3.72 (m, 1 H), 3.91 (m, 1 H), 4.60 (td, *J* = 7.6, 2.1 Hz, 1 H), 4.75 (m, 2 H), 5.26 (m, 1 H), 7.28 (d, *J* = 7.9 Hz, 2 H), 7.73 (d, *J* = 7.9 Hz, 2 H) ppm; ¹³C NMR (CDCl₃, 75 MHz) δ 10.7, 21.5, 29.0, 44.0, 52.2, 73.8, 76.2, 80.5, 88.9, 127.6, 129.4, 136.5, 143.4, 208.6 ppm. Exact mass for (C₁₆H₁₉N₁S₁O₂, EI): (calcd) 289.1137 (found) 289.1135.

2-Ethyl-3-(propa-1,2-dienyl)-1-tosyl-2,5-dihydro-1H-pyrrole (2e). ¹H NMR (CDCl₃, 300 MHz) δ 0.82 (t, *J* = 7.3 Hz, 3 H), 1.78 (m, 1 H), 1.98 (m, 1 H), 2.40 (s, 3 H), 4.11 (m, 2 H), 4.62 (m, 1 H), 4.99 (m, 1 H), 5.48 (m, 1 H), 5.78 (m, 1 H), 7.27 (d, *J* = 7.8 Hz, 2 H), 7.69 (d, *J* = 7.8 Hz, 2 H) ppm; ¹³C NMR (CDCl₃, 75 MHz) δ 7.1, 21.5, 26.4, 55.4, 67.5, 78.2, 82.2, 121.5, 127.2, 129.6, 135.1, 135.2, 143.3, 210.4 ppm. Exact mass for (C₁₆H₁₉N₁S₁O₂, HRFAB): (calcd) 290.1215, (found) 290.1213.

***N*-(Buta-2,3-dienyl)-4-methyl-*N*-(1-phenylprop-2-ynyl)benzenesulfonamide (1f).** ¹H NMR (CDCl₃, 300 MHz) δ 2.40 (d, *J* = 2.2 Hz, 1 H), 2.44 (s, 3 H), 3.71–3.77 (m, 2 H), 4.42 (m, 1 H), 4.51 (m, 1 H), 4.77 (m, 1 H), 6.11 (d, *J* = 2.2 Hz, 1 H), 7.33 (m, 5 H), 7.60 (d, *J* = 6.9 Hz, 2 H), 7.79 (d, *J* = 8.0 Hz, 2 H) ppm; ¹³C NMR (CDCl₃, 75 MHz) δ 21.8, 44.6, 53.3, 76.0, 78.4, 87.9, 128.0, 128.3, 128.6, 128.63, 128.7, 129.7, 136.0, 136.6, 143.8 ppm. Exact mass for (C₂₀H₁₉N₁S₁O₂, EI): (calcd) 337.1137, (found) 337.1137.

2-Phenyl-3-(propa-1,2-dienyl)-1-tosyl-2,5-dihydro-1H-pyrrole (2f). ¹H NMR (CDCl₃, 300 MHz) δ 2.42 (s, 3 H), 4.34 (m, 1 H), 4.45 (m, 1 H), 4.61 (m, 1 H), 4.91 (m, 1 H), 5.59 (m, 1 H), 5.76 (m, 1 H), 5.81 (m, 1 H), 7.17 (d, *J* = 8.0 Hz, 2 H), 7.27 (m, 5 H), 7.43 (d, *J* = 8.0 Hz, 2 H) ppm; ¹³C NMR (CDCl₃, 75 MHz) δ 21.6, 54.9, 55.0, 70.3, 78.7, 87.2, 121.2, 127.2, 127.9, 128.2, 128.5, 129.5, 136.2, 136.5, 140.0, 143.0, 211.4 ppm. Exact mass for (C₂₀H₁₉N₁S₁O₂, EI): (calcd) 337.1137, (found) 337.1137.

4-Methyl-*N*-(penta-3,4-dien-2-yl)-*N*-(prop-2-ynyl)benzenesulfonamide (1g). ¹H NMR (CDCl₃, 300 MHz) δ 1.26 (d, *J* = 6.2 Hz, 3 H), 2.17 (t, *J* = 2.2 Hz, 1 H), 2.43 (s, 3 H), 3.96 (dd, *J* = 18.5, 2.2 Hz, 1 H), 4.15 (dd, *J* = 18.5, 2.2 Hz, 1 H), 4.60 (m, 1 H), 4.82 (m, 2 H), 5.07 (q, *J* = 6.2 Hz, 1 H), 7.29 (d, *J* = 8.0 Hz, 2 H), 7.80 (d, *J* = 8.0 Hz, 2 H) ppm; ¹³C NMR (CDCl₃, 75 MHz) δ 18.1, 21.7, 32.2, 52.0, 72.4, 78.1, 80.4, 91.8, 127.7, 129.7, 137.8, 143.6, 208.9 ppm. Exact mass for (C₁₅H₁₇N₁S₁O₂, EI): (calcd) 275.0980, (found) 275.0982.

2-Methyl-4-(propa-1,2-dienyl)-1-tosyl-2,5-dihydro-1H-pyrrole (2g). ¹H NMR (CDCl₃, 300 MHz) δ 1.41 (d, *J* = 6.2 Hz, 3 H), 2.42 (s, 3 H), 4.04 (m, 1 H), 4.16 (m, 1 H), 4.51 (m, 1 H), 4.99 (m, 2 H), 5.40 (m, 1 H), 5.88 (m, 1 H), 7.31 (d, *J* = 8.0 Hz, 2 H), 7.72 (d, *J* = 8.0 Hz, 2 H) ppm; ¹³C NMR (CDCl₃, 75 MHz) δ 21.7, 23.0, 55.3, 64.0, 78.5, 87.7, 127.1, 127.6, 129.9, 131.4, 135.0, 143.6, 211.1 ppm. Exact mass for (C₁₅H₁₇N₁S₁O₂, EI): (calcd) 275.0980, (found) 275.0982.

***N*-(3-Cyclobutylideneallyl)-4-methyl-*N*-(prop-2-ynyl)benzenesulfonamide (1i).** ¹H NMR (CDCl₃, 300 MHz) δ 1.93 (m, 2 H), 2.01 (t, *J* = 2.2 Hz, 1 H), 2.42 (s, 3 H), 2.81–2.87 (m, 4 H), 3.81 (s, 1 H), 3.83 (s, 1 H), 4.13 (d, *J* = 2.2 Hz, 2 H), 4.98 (m, 1 H), 7.28 (d, *J* = 8.0 Hz, 2 H), 7.73 (d, *J* = 8.0 Hz, 2 H) ppm; ¹³C NMR (CDCl₃, 75 MHz) δ 17.5, 21.6, 29.6, 35.6, 46.6, 73.4, 77.2, 87.8, 103.0, 127.7, 129.5, 136.1, 143.5, 197.5 ppm. Exact mass for (C₁₇H₁₉N₁S₁O₂, EI): (calcd) 301.1137, (found) 301.1134.

3-(2-Cyclobutylidenevinyl)-1-tosyl-2,5-dihydro-1H-pyrrole (2i). ¹H NMR (CDCl₃, 300 MHz) δ 1.91 (m, 2 H), 2.33 (s, 3 H), 2.80 (m, 4 H), 4.03 (m, 2 H), 4.06 (m, 2 H), 5.38 (s, 1 H), 5.73 (m, 1 H), 7.23 (d, *J* = 8.0 Hz, 2 H), 7.64 (d, *J* = 8.0 Hz, 2 H) ppm; ¹³C NMR (CDCl₃, 75 MHz) δ 17.4, 21.5, 29.9, 54.8, 55.5, 89.8, 103.9, 120.1, 127.2, 129.7, 134.3, 135.2, 143.4, 197.4 ppm. Exact mass for (C₁₇H₁₉N₁S₁O₂, EI): (calcd) 301.1137, (found) 301.1136.

(E)-3-(Cyclohexenylmethylene)-4-methylene-1-tosylpyrrolidine (3j). ¹H NMR (CDCl₃, 300 MHz) δ 1.61 (m, 4 H), 1.93 (m, 2 H), 2.06 (m, 2 H), 2.45 (s, 3 H), 3.81 (m, 2 H), 3.85 (m, 2 H), 5.01 (s, 1 H), 5.02 (s, 1 H), 5.41–5.46 (m, 2 H), 7.30 (d, *J* = 8.0 Hz, 2 H), 7.67 (d, *J* = 8.0 Hz, 2 H) ppm; ¹³C NMR (CDCl₃, 75 MHz) δ 21.7, 22.3, 23.1, 25.4, 28.9, 45.8, 49.8, 113.3, 120.7, 126.6, 128.1, 129.7, 133.9, 136.3, 136.5, 141.4, 143.7 ppm. Exact mass for (C₁₉H₂₃N₁S₁O₂, EI): (calcd) 329.1449, (found) 329.1448.

***N*-(But-2-ynyl)-*N*-(buta-2,3-dienyl)-4-methylbenzenesulfonamide (1k).** ¹H NMR (CDCl₃, 300 MHz) δ 1.49 (t, *J* = 2.6 Hz, 3 H), 2.35 (s, 3 H), 3.77 (m, 2 H), 4.00 (q, *J* = 2.6 Hz, 2 H), 4.69 (m, 2 H), 4.97 (m, 1 H), 7.21 (d, *J* = 8.0 Hz, 2 H), 7.65 (d, *J* = 8.0 Hz, 2 H) ppm; ¹³C NMR (CDCl₃, 75 MHz) δ 7.4, 21.7, 36.6, 45.7, 71.8, 81.7, 85.8, 128.0, 129.5, 136.4, 143.5, 209.9 ppm. Exact mass for (C₁₅H₁₇N₁S₁O₂, EI): (calcd) 275.0980, (found) 275.0981.

***N*-(But-3-ynyl)-*N*-(buta-2,3-dienyl)-4-methylbenzenesulfonamide (1m).** ¹H NMR (CDCl₃, 300 MHz) δ 1.87 (t, *J* = 2.3 Hz, 1 H), 2.29 (s, 3 H), 2.36 (td, *J* = 7.6 Hz, 2.3 Hz, 2 H), 3.22 (t, *J* = 7.6 Hz, 2 H), 3.77 (m, 2 H), 4.60 (m, 2 H), 4.83 (m, 1 H), 7.17 (d, *J* = 8.0 Hz, 2 H), 7.57 (d, *J* = 8.0 Hz, 2 H) ppm; ¹³C NMR (CDCl₃, 75 MHz) δ 19.4, 21.7, 46.0, 47.5, 70.3, 76.7, 81.2, 86.1, 128.5, 129.9, 137.2, 143.6, 209.7 ppm. Exact mass for (C₁₅H₁₇N₁S₁O₂, EI): (calcd) 275.0980, (found) 275.0977.

Acknowledgment. This work was supported by the Korean Research Foundation Grant funded by the Korean Government (MOEHRD) (KRF-2005-070-C00072) and the SRC/ERC program of MOST/KOSEF (R11-2005-065). S.I.L., S.H.S., S.M.K., and K.K. thank to the BK21 fellowship.

Supporting Information Available: Characterization of new compounds and ¹H and ¹³C NMR data. This material is available free of charge via the Internet at <http://pubs.acs.org>.

JO061318Y